健康状况

16 基于循证研究的健康状况与补充剂信息

We evaluate supplements across specific hair and scalp conditions. Each condition page ranks ingredients by evidence grade, helping you find what research actually supports for your particular concern.

How We Grade Evidence

每个健康状况页面按临床证据强度对补充剂成分进行排序。以下是各等级的含义：

Strong Evidence

Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.

Good Evidence

At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.

Some Evidence

Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.

Very Early Research

In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.

产后脱发

Affects 40-50% of women postpartum

Excessive shedding Thinning around temples Reduced hair density

休止期脱发

Second most common cause of hair loss

Diffuse thinning Excessive shedding Reduced ponytail volume

压力性脱发

Increasingly common; associated with telogen effluvium

Diffuse shedding Hair thinning Slower regrowth

头皮银屑病性脱发

45-56% of psoriasis patients have scalp involvement

Thick scales Red patches Itching +1

女性型脱发

40% of women by age 50

Widening central part Diffuse crown thinning Preserved frontal hairline

年龄相关性头发稀疏

Near-universal over age 60

Gradual density reduction Finer hair texture Slower growth rate

斑秃

2% lifetime risk

Circular bald patches Exclamation point hairs Nail pitting

牵引性脱发

Common in certain hairstyle practices

Hairline recession Broken hairs Folliculitis

甲状腺相关性脱发

4-10% of general population has thyroid dysfunction

Diffuse thinning Dry brittle hair Loss of outer eyebrows

缺铁性脱发

Affects up to 60% of premenopausal women with hair loss

Diffuse thinning Increased shedding Fatigue +1

营养缺乏性脱发

Common in restrictive diets and malabsorption conditions

Diffuse thinning Dry dull hair Slow growth +1

雄激素性脱发

50% of men by age 50, 25% of women by age 50

Receding hairline Crown thinning Widening part +1

Chemotherapy-Induced Hair Loss

Affects 65-85% of chemotherapy patients depending on regimen

Rapid diffuse shedding Complete scalp hair loss Eyebrow and eyelash loss +1

Hormonal Hair Changes (PCOS & Menopause)

PCOS affects 6-12% of women; menopause-related thinning affects 40%+ of postmenopausal women

Diffuse thinning Changes in hair texture Hirsutism (PCOS) +1

Brittle Hair and Nails Syndrome

Affects approximately 20% of the general population

Dry, splitting hair Increased breakage Brittle, peeling nails +1

Scalp Inflammation (Folliculitis & Dermatitis)

Seborrheic dermatitis affects 3-5% of adults; scalp involvement very common

Scalp redness Itching and flaking Pustules around follicles +1

FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。